
Sign up to save your podcasts
Or
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763
3.9
1414 ratings
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763
11,115 Listeners
39 Listeners
4 Listeners
55 Listeners
7 Listeners
4 Listeners
3 Listeners
1 Listeners
4 Listeners
9 Listeners
41 Listeners
14 Listeners
1 Listeners
46 Listeners
0 Listeners
6 Listeners
493 Listeners
277 Listeners
3,322 Listeners
3 Listeners
87 Listeners
27 Listeners
1,084 Listeners
1,674 Listeners
23 Listeners
350 Listeners
23 Listeners
30 Listeners
364 Listeners
42 Listeners
2 Listeners
0 Listeners
0 Listeners
0 Listeners